Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 1,555,400 | 1,106,000 | 782,400 | 560,900 | 488,800 |
| Cost of Goods | 524,000 | 433,500 | 322,300 | 187,700 | 126,300 |
| Gross Profit | 1,031,400 | 672,500 | 460,100 | 373,200 | 362,500 |
| Operating Expenses | 597,600 | 558,900 | 370,600 | 249,600 | 257,300 |
| Operating Income | 433,800 | 114,100 | 89,800 | 124,300 | 105,500 |
| Interest Expense | 31,300 | 38,400 | 9,900 | 6,600 | 7,600 |
| Other Income | 4,700 | 1,700 | 1,600 | 900 | 1,300 |
| Pre-tax Income | 407,200 | 77,400 | 81,500 | 118,600 | 99,200 |
| Income Tax | 102,100 | 22,900 | 18,800 | 36,000 | 36,700 |
| Net Income Continuous | 305,100 | 54,500 | 62,700 | 82,600 | 62,500 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -10,700 |
| Net Income | $305,100 | $54,500 | $62,700 | $82,600 | $51,800 |
| EPS Basic Total Ops | 5.79 | 1.06 | 1.25 | 1.98 | 1.29 |
| EPS Basic Continuous Ops | 5.79 | 1.06 | 1.25 | 1.98 | 1.56 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | -0.27 |
| EPS Diluted Total Ops | 5.67 | 1.04 | 1.22 | 1.71 | 1.13 |
| EPS Diluted Continuous Ops | 5.67 | 1.04 | 1.22 | 1.64 | 1.35 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | -0.22 |
| EPS Diluted Before Non-Recurring Items | 7.88 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $551,800 | $227,800 | $152,900 | $168,600 | $143,700 |